Live in-person:

6 - 9 February 2023

Dubai World Trade Centre

 16 Jan - 9 Mar 2023

Online

The convergence of diagnostics and population health

 


Al Borg Diagnostics

 

 Wednesday 8th February I 10:30 - 13:00

 Johannesburg room I Z1.D10

 

 

 

Sessions

Presenter

Khosrow R. Shotorbani, CEO, Lab 2.0

Learning objectives

  • Understand the key assets of clinical lab in improving outcome and reduce total cost of delivery as we transition from volume to value-based health care
  • Understand the key attributes of longitudinal laboratory data in proactive risk stratification of population
  • Understand laboratory medicine’s essential practice of developing proactive chronic conditions surveillance
  • Understand the role of a clinical lab 2.0 lab-Initiated care model for early detection and early care coordination

Presenter

Steven Goldberg, MD, MBA, Vice President, Chief Health Officer, Employee & Population Health​, Quest Diagnostics 

Learning objectives

Quest diagnostics approach and action improving population health management 


Company bio

 

Established in 1999, when it opened its first laboratory in Jeddah, Saudi Arabia, Al Borg Diagnostics managed to expand to all major cities in the Kingdom of Saudi Arabia by the year 2004. Today, Al Borg Diagnostics has become the largest chain of private laboratories in the Gulf Cooperation Council countries and is currently expanding to the African continent. Al Borg Diagnostics serves about 15,000 visiting customers daily, and more than 5,000 hospital's and clinic's laboratories, in addition to cooperating with various pharmaceutical companies in the field of precision medicine.

Based on our core values of providing high quality services, adopting best practices, and more than 25 years of experience in this field, Al Borg Diagnostics has become the leading provider of integrated laboratory services and solutions to meet the needs of citizens and residents, as well as health care providers, practitioners, international pharmaceutical companies, and research centers in the countries in which we are present in. With your continuous support and trust, we look forward to further progress in the future and to contribute effectively in the health sector field and the 2030 vision in the Kingdom.

Al Borg Dx and Quest offer you high-quality testing and Laboratory Solutions to reduce your healthcare spending, generate financial results, and provide cost-efficient diagnostic testing to help hospitals find the right ways. We offer Outsourcing/Lab Management Solutions, Population Health Management, IT solutions, Logistics-Procurement, while maintaining Patient Safety/Rights, to serve individuals, communities, and populations. Our robust infrastructure, strong technological partnerships with some of the world leaders in automation and technology and dedicated team brings forth a value proposition combining reliability, convenience, and innovation to hospital labs.


Presenters
 

 

Khosrow R. Shotorbani
CEO, Lab 2.0

Khosrow Shotorbani is the CEO and founder of the newly established Lab 2.0 Strategic Services, LLC.  He is a member of the board, and President, Executive Director of Project Santa Fe Foundation, advocating for Clinical Lab 2.0 movement.
Mr. Shotorbani was instrumental in the creation of Project Santa Fe—a initiative with like-minded executives—helping to drive new frontiers that will define future economic valuation. Mr. Shotorbani served as Senior Vice President, co-Director of Business Development and Director of Business Innovations at ARUP.


Dr. Steven Goldberg, MD, MBA
Vice President, Chief Health Officer, Employee & Population Health

Dr. Steven Goldberg, is responsible for improving employee health, member healthcare experience, clinical outcomes and bending cost trends for Quest’s employees and health plan beneficiaries. In addition, he provides support to our Diagnostic Services businesses when engaging health plan and employer customers. His research work focuses on driving best employer health outcomes and value, including the implementation of virtual comprehensive medication management, enhanced by pharmacogenomics in employer populations.